DK2621481T3 - Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser - Google Patents

Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser Download PDF

Info

Publication number
DK2621481T3
DK2621481T3 DK11764655.4T DK11764655T DK2621481T3 DK 2621481 T3 DK2621481 T3 DK 2621481T3 DK 11764655 T DK11764655 T DK 11764655T DK 2621481 T3 DK2621481 T3 DK 2621481T3
Authority
DK
Denmark
Prior art keywords
castration
vegf
met
treatment
prostate cancer
Prior art date
Application number
DK11764655.4T
Other languages
English (en)
Other versions
DK2621481T4 (da
Inventor
David Smith
Maha Hussain
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44741730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2621481(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of DK2621481T3 publication Critical patent/DK2621481T3/da
Application granted granted Critical
Publication of DK2621481T4 publication Critical patent/DK2621481T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DK11764655.4T 2010-09-27 2011-09-26 Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser DK2621481T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38695910P 2010-09-27 2010-09-27
US201161481671P 2011-05-02 2011-05-02
PCT/US2011/053233 WO2012044572A1 (en) 2010-09-27 2011-09-26 Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases

Publications (2)

Publication Number Publication Date
DK2621481T3 true DK2621481T3 (da) 2019-10-21
DK2621481T4 DK2621481T4 (da) 2023-01-09

Family

ID=44741730

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11764655.4T DK2621481T4 (da) 2010-09-27 2011-09-26 Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser

Country Status (22)

Country Link
US (5) US20140057943A1 (da)
EP (1) EP2621481B2 (da)
JP (2) JP6158705B2 (da)
KR (1) KR101882328B1 (da)
CN (1) CN103402505A (da)
AR (1) AR085195A1 (da)
AU (2) AU2011307304C1 (da)
BR (1) BR112013007220A2 (da)
CA (1) CA2812750C (da)
DK (1) DK2621481T4 (da)
EA (1) EA027476B1 (da)
ES (1) ES2754973T5 (da)
FI (1) FI2621481T4 (da)
HU (1) HUE045810T2 (da)
IL (1) IL225507B (da)
MX (1) MX352926B (da)
PL (1) PL2621481T5 (da)
PT (1) PT2621481T (da)
SI (1) SI2621481T2 (da)
TW (2) TW201302709A (da)
UA (1) UA114172C2 (da)
WO (1) WO2012044572A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4014971A1 (en) 2010-07-16 2022-06-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
US20140057943A1 (en) 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) * 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
MX351133B (es) * 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
TWI642650B (zh) 2011-10-20 2018-12-01 艾克塞里克斯公司 用於製備喹啉衍生物之方法
TWI662962B (zh) * 2011-11-08 2019-06-21 艾克塞里克斯公司 治療癌症之方法
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 Ｎ­（４­〔［６,７­비스（메틸옥시）퀴놀린­４­일］옥시〕페닐）­ｎ′­（４­플루오로페닐）시클로프로판­１,１­디카복사미드의 대사물
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
US20160082019A1 (en) * 2013-04-04 2016-03-24 Exelixis, Inc. Drug Combinations to Treat Cancer
EP3105204A1 (en) 2014-02-14 2016-12-21 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
WO2016022697A1 (en) 2014-08-05 2016-02-11 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3219205A1 (en) * 2016-03-18 2017-09-20 Nihon Medi-Physics Co., Ltd. Method for producing a non human animal model of osteoblastic bone metastasis
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN108503650B (zh) * 2017-02-27 2021-02-12 北京赛特明强医药科技有限公司 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
BR112020012875A2 (pt) 2017-12-27 2021-01-05 St. Jude Children¿S Research Hospital, Inc. Moduladores de pequenas moléculas das pantotenato quinases
WO2019133632A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Methods of treating disorders associated with castor
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CA3090876C (en) * 2018-02-11 2022-12-06 Beijing Scitech-Mq Pharmaceuticals Limited Dioxinoquinoline compounds, preparation method and uses thereof
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
EP4262814A1 (en) * 2020-12-16 2023-10-25 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1447405A4 (en) 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
US7166722B2 (en) 2002-10-21 2007-01-23 Kirin Beer Kabushiki Kaisha N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
AU2003280599A1 (en) 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
JP4593464B2 (ja) 2002-11-04 2010-12-08 アストラゼネカ アクチボラグ Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体
AU2003300898A1 (en) 2002-12-13 2004-07-09 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
PL377686A1 (pl) 2002-12-18 2006-02-06 Pfizer Products Inc. Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
AU2003299943A1 (en) 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
AU2003292838A1 (en) 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
AU2006231646A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
WO2008035209A2 (en) 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CN111643496A (zh) 2006-12-14 2020-09-11 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
RU2495044C2 (ru) * 2007-08-29 2013-10-10 Метилджен Инк. Ингибиторы активности протеинтирозинкиназы
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
TW201035017A (en) 2008-09-26 2010-10-01 Smithkline Beecham Corp Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
US20110229469A1 (en) 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
AU2009313970A1 (en) 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
JP2010126530A (ja) * 2008-12-01 2010-06-10 Takeda Chem Ind Ltd 縮合複素環誘導体およびその用途
US20130030172A1 (en) 2008-12-04 2013-01-31 Exelixis, Inc. Methods of Preparing Quinoline Derivatives
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EA201200144A1 (ru) 2009-07-17 2012-08-30 Экселиксис, Инк. Кристаллические формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2475390A4 (en) 2009-09-09 2014-01-01 Quintiles Transnat Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
TW201202228A (en) 2010-03-12 2012-01-16 Exelixis Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009723A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
EP4014971A1 (en) 2010-07-16 2022-06-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
US20140057943A1 (en) 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
EP2643001A4 (en) 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
TWI642650B (zh) 2011-10-20 2018-12-01 艾克塞里克斯公司 用於製備喹啉衍生物之方法
TWI662962B (zh) 2011-11-08 2019-06-21 艾克塞里克斯公司 治療癌症之方法
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 Ｎ­（４­〔［６,７­비스（메틸옥시）퀴놀린­４­일］옥시〕페닐）­ｎ′­（４­플루오로페닐）시클로프로판­１,１­디카복사미드의 대사물
US20160082019A1 (en) 2013-04-04 2016-03-24 Exelixis, Inc. Drug Combinations to Treat Cancer

Also Published As

Publication number Publication date
SI2621481T1 (sl) 2019-11-29
AR085195A1 (es) 2013-09-18
CA2812750A1 (en) 2012-04-05
EP2621481A1 (en) 2013-08-07
FI2621481T4 (fi) 2023-01-13
EP2621481B1 (en) 2019-08-14
PL2621481T3 (pl) 2020-03-31
ES2754973T5 (es) 2023-03-13
BR112013007220A2 (pt) 2017-08-08
US20160220554A1 (en) 2016-08-04
MX2013003594A (es) 2013-08-01
AU2016204747A1 (en) 2016-07-28
AU2011307304C1 (en) 2016-10-20
ES2754973T3 (es) 2020-04-21
US20240156803A1 (en) 2024-05-16
JP6158705B2 (ja) 2017-07-05
EA201390465A1 (ru) 2013-08-30
US11612597B2 (en) 2023-03-28
SI2621481T2 (sl) 2023-02-28
IL225507A0 (en) 2013-06-27
AU2011307304B2 (en) 2016-04-14
EP2621481B2 (en) 2022-10-19
US20140057943A1 (en) 2014-02-27
US20230301980A1 (en) 2023-09-28
PT2621481T (pt) 2019-11-19
EA027476B1 (ru) 2017-07-31
MX352926B (es) 2017-12-14
AU2011307304A1 (en) 2013-05-02
UA114172C2 (uk) 2017-05-10
CA2812750C (en) 2020-10-06
JP2013537916A (ja) 2013-10-07
IL225507B (en) 2019-08-29
PL2621481T5 (pl) 2023-03-13
TW201302709A (zh) 2013-01-16
DK2621481T4 (da) 2023-01-09
US20200330450A1 (en) 2020-10-22
KR20140025304A (ko) 2014-03-04
JP2017149714A (ja) 2017-08-31
US11969419B2 (en) 2024-04-30
CN103402505A (zh) 2013-11-20
TW201738213A (zh) 2017-11-01
WO2012044572A1 (en) 2012-04-05
KR101882328B1 (ko) 2018-07-27
HUE045810T2 (hu) 2020-01-28

Similar Documents

Publication Publication Date Title
DK2621481T4 (da) Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK2435432T6 (da) Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme
DK2507211T3 (da) Apoptosefremkaldende midler til behandling af cancer og immun- og autoimmun-sygdomme
DK2511264T3 (da) Apoptose-inducerende midler til behandling af cancer og immunsygdomme og autoimmune sygdomme
DK3838923T3 (da) Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
DK2785744T3 (da) Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK2790738T3 (da) Biomarkører for kollateral geninaktivering og mål for cancerterapi
DK3400944T3 (da) Ibat-inhibitorer til behandling af leversygdomme
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
BR112013012078A2 (pt) inibidores de nampt e rock
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK2544679T3 (da) Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK3650125T3 (da) Væskeforstøver og fremgangsmåder
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
EA202190820A1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
DK2576638T3 (da) Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf